TrialDiabetes, obesity & metabolism2019

Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.

Olivia M Farr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.